glp 1 drugs and parkinson's disease GLP-1 Receptor Agonists: A New Treatment in Researching GLP-1 drugs and Parkinson's

Genetic Predispositions That May Influence GLP-1 Response Individual genetic variants in GLP-1 receptor signaling pathways (GLP1R rs6923761), appetite regulation (FTO rs9939609, MC4R rs17782313), and GIP signaling (GIPR rs1800437) may predict predispositions toward stronger or more modest metabolic responses

Theres always a concern about: Do these results generalize? More clinical trials needed Thats why more randomized controlled trials are needed, Simmons emphasized

Adv Exp Med Biol (2019) 1184:187203

and liraglutide (Saxenda, Novo Nordisk)

Hager, M

Cells were seeded in 96-well plates at a density of 35,000 cells per well and transiently transfected using Lipofectamine 2000 according to the manufacturers protocol